Evidence map›Paper›PMID 21769815›Full record

ReviewCardiology journal2011

Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease.

Joseph Ramli, Pedro CalderonArtero, Robert C Block, Shaker A Mousa

Abstract readReview
In one paragraph

Review in Cardiology journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joseph RamliPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY 12144, USA.
Pedro CalderonArtero
Robert C Block
Shaker A Mousa

Funding

The University of Rochester's Clinical and Translational Science InstituteKL2RR024136 · NCRR · UNIVERSITY OF ROCHESTER · PI PEARSON, THOMAS ARTHUR · 2006 to 2011
$4.3M
Structure-Based Search for Novel Antihypercholestrolemic AgentR44HL092712 · NHLBI · SHIFA BIOMEDICAL CORPORATION · PI ABDEL-MEGUID, SHERIN S · 2010 to 2011
$1.3M
Novel Modulators of LDL MetabolismR43HL096167 · NHLBI · SHIFA BIOMEDICAL CORPORATION · PI ELSHOURBAGY, NABIL A · 2009 to 2009
$276k
NCRR NIH HHS KL2 RR 024136NCRR NIH HHS KL2 RR024136NHLBI NIH HHS R43 HL096167NHLBI NIH HHS R44 HL092712
6 · The paper itself

Abstract

The endothelium lies in a strategic anatomical position between the circulating blood and the vascular smooth-muscle cells. It is a source of vasodilators such as nitric oxide, prostacyclin, and hyperpolarizing factor as well as heparin-like substances and other molecules with antiproliferative properties. These effects of endothelial cells may explain why platelets and monocytes usually do not adhere at the blood vessel wall. However, under pathological conditions, endothelial dysfunction occurs and significantly contributes to the increase of platelet- -vessel wall interaction, vasoconstriction, pro-inflammation, and proliferation. Under these conditions, endothelium-dependent vasodilation is reduced, and endothelium-dependent constrictor responses are augmented. Upon vessel wall injury, the platelets rapidly adhere to the exposed sub-endothelial matrix, which is mediated by several cellular receptors present on platelets or endothelial cells and various adhesive proteins. Subsequent platelet activation results in the recruitment of additional platelets and the generation of platelet aggregates, so forming a stable platelet plug. Therapeutic strategies aimed at improving or preserving endothelial function therefore may be promising in terms of preventing and treating coronary artery disease. Diagnostic modalities for assessing endothelial function should allow for the early detection of vascular endothelial dysfunction before the manifestation of serious adverse vascular disorders.

Indexed as

Genetic TherapyAnimalsCardiovascular AgentsCardiovascular DiseasesEndothelium, VascularHumansTreatment OutcomeCardiovascular Agents

Identifiers

PMID21769815
PMCPMC3342824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.